AranespThis is an RSS file. You can use it to subscribe to this data in your favourite RSS reader, such as GoogleReader, or to display this data on your own website or blog. Subscribe to this data using MyMedWorm.Subscribe to this data using GoogleReader.Subscribe to this data using Bloglines.Subscribe to this data using MyYahoo.

This page shows you your search results in order of date.

Pages: 1 2 3 4 5 6 7 8

370 records returned

Darbepoetin Alfa and History of Thromboembolic Events [CORRESPONDENCE]Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - November 18, 2009 Category: Cancer & Oncology Authors: Ferretti, Felici, Cognetti Tags: CORRESPONDENCE Source Type: journals

A Trial of Darbepoetin Alfa in Type 2 Diabetes and Chronic Kidney DiseaseEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Anemia is associated with an increased risk of cardiovascular and renal events among patients with type 2 diabetes and chronic kidney disease. This placebo-controlled trial randomly assigned such patients to receive darbepoetin alfa or placebo. The two composite end points were death or cardiovascular disease and death or end-stage renal disease. Darbepoetin alfa did not reduce either outcome and was associated with an increased risk of stroke. (Source: New England Journal of Medicine)
Source: New England Journal of Medicine - November 18, 2009 Category: Internal Medicine Authors: Pfeffer, M. A., Burdmann, E. A., Chen, C.-Y., Cooper, M. E., de Zeeuw, D., Eckardt, K.-U., Feyzi, J. M., Ivanovich, P., Kewalramani, R., Levey, A. S., Lewis, E. F., McGill, J. B., McMurray, J. J.V., Parfrey, P., Parving, H.-H., Remuzzi, G., Singh, A. K., Tags: ORIGINAL ARTICLES Source Type: journals

CME: A Trial of Darbepoetin Alfa in Type 2 Diabetes and Chronic Kidney DiseaseEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
(No abstract is available for this citation) (Source: New England Journal of Medicine)
Source: New England Journal of Medicine - November 18, 2009 Category: Internal Medicine Source Type: journals

Video Day in Review from AHA 2009 with Dr. Melissa Walton-Shirley: Monday, November 16Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Join Dr. Walton-Shirley for a review of ARBITER 6-HALTS, Primary PCI in Massachusetts, high ionizing radiation, soybeans and omega-3 fatty acid, video games, anemia and transfusion, and darbepoetin alfa. Medscape Cardiology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 17, 2009 Category: Consumer Health News Tags: Cardiology Source Type: news

AHA: Stroke, VTE More Common with Darbepoetin (CME/CE)Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
ORLANDO (MedPage Today) -- Treating patients with diabetes, kidney disease and anemia with the colony stimulating factor darbepoetin (Aranesp) to improve their hemoglobin levels appears to cause more problems than it solves, researchers reported here. (Source: MedPage Today Nephrology)
Source: MedPage Today Nephrology - November 17, 2009 Category: Urology & Nephrology Source Type: news

Anemia TREATment fails to yield CV benefits, ups stroke riskEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
The risks of using the erythropoiesis-stimulating agent, darbepoetin alpha, to treat anemia in patients with Type 2 diabetes and chronic kidney disease far outweigh any modest benefits, according to data from the Trial to Reduce Cardiovascular Events with Aranesp Therapy. (Source: MedWire News - Cardiology)
Source: MedWire News - Cardiology - November 17, 2009 Category: Cardiology Source Type: news

Clinical Trial Summary: Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT — Presented at AHA 2009)Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Although erythropoiesis-stimulating agents (ESAs) are widely used in patients with anemia and chronic kidney disease (CKD) who are not on dialysis, randomized data to support this approach are not available. The TREAT trial sought to test the hypothesis that the use of ESAs in patients with diabetes. . . (Source: Cardiosource)
Source: Cardiosource - November 16, 2009 Category: Cardiology Source Type: organizations

CHOICE, an international, observational study to examine current practice use of darbepoetin alfa in the management of chemotherapy-induced anaemiaEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Introduction: In February 2008, the European product label for darbepoetin alfa (DA) in the treatment of chemotherapy-induced anaemia (CIA) was changed to stipulate target haemoglobin (Hb) values between 10 and 12g/dL. EORTC guidelines on ESA use state similar Hb target levels. The primary aim of this study is to assess adherence to the recommended Hb target range in patients (pts) receiving DA in routine clinical practice.Methods: This prospective, multicenter, observational study evaluated the routine clinical practice use of DA in 11 European countries in pts with various non-myeloid malignancies (breast, colorectal, ov...
Source: European Journal of Integrative Medicine - November 13, 2009 Category: Complementary Medicine Authors: S. Van Belle, P. Dalivoust, A. Reinthaller, D. Tzanninis, K. Urbanski, L. Hamilton, B. Pujol Source Type: journals

Anemia treatment fails to improve outcomes in Type 2 diabetics with CKDEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Results from the TREAT study show that darbepoetin alfa treatment for anemia does not improve cardiovascular or renal outcomes or related mortality of patients with Type 2 diabetes, chronic kidney disease, and moderate anemia. (Source: MedWire News - Cardiology)
Source: MedWire News - Cardiology - November 4, 2009 Category: Cardiology Source Type: news

C.E.R.A. once every 4 weeks in patients with chronic kidney disease not on dialysis: The ARCTOS extension studyEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
C.E.R.A., a continuous erythropoietin receptor activator is approved for the treatment of anemia in patients with chronic kidney disease (CKD). The ARCTOS (administration of C.E.R.A. in CKD patients to treat anemia with a twice-monthly schedule) phase 3 study demonstrated the efficacy and safety of C.E.R.A. in correcting anemia when administered once every 2 weeks (Q2W) subcutaneously in patients with CKD not on dialysis. We assessed the feasibility and long-term safety of converting patients who responded to treatment with C.E.R.A. Q2W to C.E.R.A. once every 4 weeks (Q4W) during a 24-week extension period. After the core ...
Source: Hemodialysis International - November 4, 2009 Category: Hematology Authors: Michèle KESSLER, Alberto MARTÍNEZ-CASTELAO, Kostas C. SIAMOPOULOS, Giuseppe VILLA, Bruce SPINOWITZ, Frank C. DOUGHERTY, Ulrich BEYER Source Type: journals

Treating Anemia Does Not Reduce the Risk for Cardiovascular or Renal Events in Diabetics With Renal DiseaseEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Anemia treatment with darbepoetin alfa is no better than placebo at reducing mortality, heart failure, heart attacks, or dialysis need in patients with diabetes, anemia, and chronic kidney disease. Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 3, 2009 Category: Consumer Health News Tags: Nephrology Source Type: news

Darbepoetin Alfa Fails to Cut Mortality and Cardiac, Renal EventsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
For patients with chronic kidney disease, type 2 diabetes, and anemia, raising hemoglobin levels with darbepotein alfa does not improve the combined risk of death and major cardiovascular and renal events,... (Source: OncologySTAT Latest News)
Source: OncologySTAT Latest News - November 3, 2009 Category: Cancer & Oncology Source Type: news

Anemia treatment fails to improve outcomes in Type 2 diabetics with CKDEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Results from the TREAT study show that darbepoetin alfa treatment for anemia does not improve cardiovascular or renal outcomes or related mortality of patients with Type 2 diabetes, chronic kidney disease, and moderate anemia. (Source: MedWire News - Diabetes)
Source: MedWire News - Diabetes - November 3, 2009 Category: Endocrinology Source Type: news

Darbepoetin Alfa Associated with Heightened Stroke RiskEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
(Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - November 2, 2009 Category: Primary Care Tags: Medical News Source Type: info

Benefits, Risks of Darbepoetin Alfa in Diabetes AssessedEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
In patients with diabetes, chronic kidney disease and anemia, darbepoetin alfa does not reduce death, cardiovascular or renal events, and may be linked to an increased risk of stroke, according to a study published online Oct. 30 in the New England Journal of Medicine. (Source: Modern Medicine)
Source: Modern Medicine - November 2, 2009 Category: Journals (General) Source Type: info

Anemia Drug May Raise Stroke Risk in Kidney PatientsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Use of Aranesp should be reserved for the most seriously ill, experts say Source: HealthDay Related MedlinePlus Topics: Anemia, Diabetic Kidney Problems, Drug Safety (Source: MedlinePlus Health News)
Source: MedlinePlus Health News - November 1, 2009 Category: Consumer Health News Source Type: consumer

A Trial of Darbepoetin Alfa in Type 2 Diabetes and Chronic Kidney DiseaseEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
This study is expected to drive much discussion and influence guidelines and clinical practice. © Nephrology Now editors for Nephrology Now, 2009. | Permalink | 2 comments | Add to del.icio.us Post tags: (Source: Nephrology Now)
Source: Nephrology Now - November 1, 2009 Category: Urology & Nephrology Authors: Nephrology Now editors Tags: Anemia Chronic Kidney Disease Source Type: journals

Treatment of Anemia in Chronic Kidney Disease — Strategies Based on EvidenceEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
This editorial provides insight into the interpretation of the TREAT study, “A Trial of Darbepoetin Alfa in Type 2 Diabetes and Chronic Kidney Disease”. © Nephrology Now editors for Nephrology Now, 2009. | Permalink | Add comment! | Add to del.icio.us Post tags: (Source: Nephrology Now)
Source: Nephrology Now - November 1, 2009 Category: Urology & Nephrology Authors: Nephrology Now editors Tags: Anemia Chronic Kidney Disease Source Type: journals

Anemia Drug May Raise Stroke Risk in Kidney PatientsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Use of Aranesp should be reserved for the most seriously ill, experts say (Source: Forbes.com Health News)
Source: Forbes.com Health News - October 31, 2009 Category: Consumer Health News Source Type: news

Amgen's Anemic ResultsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
The company's best-selling Aranesp drug doubles the risk that kidney patients will suffer a stroke. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - October 31, 2009 Category: Pharmaceuticals Source Type: news

No TREAT: Darbepoetin alfa fails to reduce CV or renal events in anemic diabetics with CKDEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
No differences were seen between groups, except in strokes, which were twice as high in the active treatment group. Anticipated improvements in fatigue scores were modest, and not clinically meaningful, investigators say. (Source: theHeart.org)
Source: theHeart.org - October 31, 2009 Category: Cardiology Source Type: info

Study Finds Stroke Risk From Anemia Drug AranespEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Aranesp nearly doubles stroke risk in diabetics with anemia and kidney problems, study finds (Source: ABC News: Health)
Source: ABC News: Health - October 31, 2009 Category: Consumer Health News Source Type: news

Study finds stroke risk from anemia drug AranespEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
A new study raises fresh safety concerns about widely used anemia medicines, finding that the drug Aranesp nearly doubled the ... (Source: USATODAY.com Health)
Source: USATODAY.com Health - October 31, 2009 Category: Consumer Health News Source Type: news

ASN: No Clinical Benefit for ESA in Anemic Patients with Diabetes, CKD (CME/CE)Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
SAN DIEGO — For patients with type 2 diabetes, chronic kidney disease, and anemia, darbepoetin alfa (Aranesp) failed to improve most clinical outcomes compared with placebo and nearly doubled the risk of stroke, a large, multicenter trial showed. (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - October 31, 2009 Category: Cardiology Source Type: news

Clinical Trial Summary: Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT)Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Although erythropoiesis-stimulating agents (ESAs) are widely used in patients with anemia and chronic kidney disease (CKD) who are not on dialysis, randomized data to support this approach are not available. The TREAT trial sought to test the hypothesis that the use of ESAs in patients with diabetes. . . (Source: Cardiosource)
Source: Cardiosource - October 31, 2009 Category: Cardiology Source Type: organizations

States Sue Amgen Over Sales PracticesEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Fourteen states sued Amgen alleging the drug-maker provided doctors with retreats and other incentives to prescribe anemia-drug Aranesp. (Source: WSJ.com: Health)
Source: WSJ.com: Health - October 30, 2009 Category: Pharmaceuticals Tags: FREE Source Type: news

Aranesp nearly doubles stroke risk in diabetics with anemia and kidney problems, study findsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
A new study raises fresh safety concerns about widely used anemia medicines, finding that the drug Aranesp nearly doubled the risk of stroke in people with diabetes and chronic kidney problems who are not yet sick enough to need dialysis. The study is... (Source: OrlandoSentinel: Medical Research)
Source: OrlandoSentinel: Medical Research - October 30, 2009 Category: American Health Source Type: news

Anemia Treatment of Patients with Diabetes and Chronic Kidney Disease is No More Effective Than Placebo and Carries RisksEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Researchers found no significant differences in deaths, heart attacks, heart failure, or need for dialysis compared to placebo. However, researchers found an increased risk of stroke among those assigned to darbepoetin alfa compared to placebo. (Source: BWH for Journalists)
Source: BWH for Journalists - October 30, 2009 Category: Research Source Type: organizations

Anemia Treatment of Patients with Diabetes and Chronic Kidney Disease is No More Effective Than Placebo and Carries RisksEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Researchers found no significant differences in deaths, heart attacks, heart failure, or need for dialysis compared to placebo. However, researchers found an increased risk of stroke among those assigned to darbepoetin alfa compared to placebo. (Source: BWH News)
Source: BWH News - October 30, 2009 Category: Hospital Management Source Type: organizations

A Trial of Darbepoetin Alfa in Type 2 Diabetes and Chronic Kidney DiseaseEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Background Anemia is associated with an increased risk of cardiovascular and renal events among patients with type 2 diabetes and chronic kidney disease. Although darbepoetin alfa can effectively increase hemoglobin ... (Source: New England Journal of Medicine)
Source: New England Journal of Medicine - October 30, 2009 Category: Internal Medicine Authors: Pfeffer, M. A., Burdmann, E. A., Chen, C.-Y., Cooper, M. E., de Zeeuw, D., Eckardt, K.-U., Feyzi, J. M., Ivanovich, P., Kewalramani, R., Levey, A. S., Lewis, E. F., McGill, J. B., McMurray, J. J.V., Parfrey, P., Parving, H.-H., Remuzzi, G., Singh, A. K., Tags: ORIGINAL ARTICLES Source Type: journals

Large Study of Anemia Treatment in Chronic Kidney Disease Patients Not on Dialysis Published in the New England Journal of Medicine Failed to Meet Primary Efficacy EndpointsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
THOUSAND OAKS, Calif., Oct. 30 /PRNewswire-FirstCall/—Amgen (Nasdaq: AMGN) today announced the publication of results from TREAT (the Trial to Reduce Cardiovascular Events with Aranesp?? Therapy), a large, randomized, double-blind, placebo-controlled, Phase 3 pivotal study of patients with chronic kidney disease (CKD) not on dialysis, moderate anemia and type-2 diabetes. The study, published online today in the New England Journal of Medicine and presented at the annual meeting of the American Society of Nephrology (ASN), failed to meet its primary objectives of demonstrating a reduction in all-cause mortality, cardiovas...
Source: Amgen News Service - October 30, 2009 Category: Pharmaceuticals Authors: pmannle at amgen.com Tags: Press Releases Source Type: organizations

The safety and tolerability of darbepoetin alfa in patients with anaemia and symptomatic heart failureEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusion Darbepoetin alfa was well tolerated with an AE profile similar to placebo in HF subjects treated to a target Hb of 14.0 ± 1.0 g/dL. Contrary to recent data in other patient populations, there was no evidence of increased risk of mortality or cardiovascular events. (Source: European Journal of Heart Failure)
Source: European Journal of Heart Failure - October 29, 2009 Category: Cardiology Authors: Klapholz, M., Abraham, W. T., Ghali, J. K., Ponikowski, P., Anker, S. D., Knusel, B., Sun, Y., Wasserman, S. M., van Veldhuisen, D. J. Tags: ANAEMIA Source Type: journals

Effect of darbepoetin alfa on renal anemia in Japanese hemodialysis patients.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
CONCLUSION: Darbepoetin alfa increases the Hgb value effectively in Japanese hemodialysis patients. Although no serious adverse events were apparent in our short-term analysis, the incidence of hypertension and excessive increase of the Hgb value must be noted. PMID: 19856789 [PubMed - in process] (Source: Arzneimittel-Forschung)
Source: Arzneimittel-Forschung - October 29, 2009 Category: Drugs & Pharmacology Authors: Kusaba T, Ishida R, Nakayama M, Kato H, Uchiyama H, Sato K, Mori Y, Matsubara H, Kajita Y Tags: Arzneimittelforschung Source Type: journals

Meeting New Challenges in the Management of Anemia of Chronic Kidney Disease Through Collaborative Care with Pharmacists (November).Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
CONCLUSIONS: An approach to CKD-associated anemia management that involves collaboration with pharmacists is essential to achieve patient-specific, cost-effective ESA therapy. PMID: 19826095 [PubMed - as supplied by publisher] (Source: The Annals of Pharmacotherapy)
Source: The Annals of Pharmacotherapy - October 12, 2009 Category: Drugs & Pharmacology Authors: Bacchus S, O'Mara N, Manley H, Fishbane S Tags: Ann Pharmacother Source Type: journals

Maintaining high hemoglobin levels improved the left ventricular mass index and quality of life scores in pre-dialysis Japanese chronic kidney disease patientsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusions Targeting a higher Hb around 12 g/dl was more beneficial than targeting conventional Hb in terms of reduction of LVMI and QOL. Further studies to determine the appropriate Hb target are necessary. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s10157-009-0212-4Authors Hideki Hirakata, Fukuoka Red Cross Hospital 3-1-1 Ogusu Minami-ku Fukuoka Fukuoka 815-8555 JapanYoshiharu Tsubakihara, Osaka General Medical Center Osaka JapanFumitake Gejyo, Niigata University Medical and Dental Hospital Niigata JapanShinichi Nishi, Niigata University Medical and Dental Hospital Niigata...
Source: Clinical and Experimental Nephrology - September 17, 2009 Category: Urology & Nephrology Tags: Clinical and Experimental Nephrology Source Type: journals

Amgen Announces Top-Line Results of Trial to Reduce Cardiovascular Events With Aranesp(R) Therapy (TREAT) in CKD Patients With Type-2 DiabetesEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
While not a peer-reviewed publications, Nephrology Now readers will likely be interested in this preliminary announcements of key findings of the TREAT study which looks at anemia treatment in CKD patients with diabetes. © Nephrology Now editors for Nephrology Now, 2009. | Permalink | Add comment! | Add to del.icio.us Post tags: (Source: Nephrology Now)
Source: Nephrology Now - September 14, 2009 Category: Urology & Nephrology Authors: Nephrology Now editors Tags: Anemia Chronic Kidney Disease Source Type: journals

Darbepoetin alfa for treating chemotherapy-induced anemia in patients with a baseline hemoglobin level < 10 g/dL versus [greater than or equal to] 10 g/dL: an exploratory analysis from a randomized, double-blind, active-controlled trialEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Background: Several studies have shown that darbepoetin alfa, an erythropoiesis-stimulating agent (ESA), can reduce transfusions and increase hemoglobin (Hb) levels in patients with chemotherapy-induced anemia (CIA). Recent safety concerns, however, have prompted changes to ESA product information. In the European Union and United States, ESA therapy initiation for CIA is now recommended at a Hb level [less than or equal to]10g/dL. The present exploratory analysis examined how ESA initiation at this Hb level may impact patient care. Methods: Data from a phase 3 randomized trial were retrospectively reanalyzed. CIA patients...
Source: BMC Cancer - September 2, 2009 Category: Cancer & Oncology Authors: Johan VansteenkisteMichael HedenusPere GasconCarsten BokemeyerHeinz LudwigJan VermorkenLisa HamiltonKen BridgesBeatriz Pujol Source Type: journals

Pretreatment with darbepoetin attenuates renal injury in a rat model of Cisplatin-induced nephrotoxicity.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
CONCLUSIONS: DPO exhibits a renoprotective effect in experimental cisplatin-induced renal injury, the mechanism of which may involve DPO antiinflammatory and antiapoptotic effects. PMID: 19721861 [PubMed - in process] (Source: The Korean Journal of Internal Medicine)
Source: The Korean Journal of Internal Medicine - August 31, 2009 Category: Internal Medicine Authors: Choi DE, Jeong JY, Lim BJ, Lee KW, Shin YT, Na KR Tags: Korean J Intern Med Source Type: journals

Amgen Announces Top-Line Results Of Trial To Reduce Cardiovascular Events With Aranesp(R) Therapy (TREAT) In CKD Patients With Type-2 DiabetesEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Amgen (Nasdaq: AMGN) announced that in a large, randomized, double-blind, placebo-controlled, Phase 3 study of patients with chronic kidney disease (CKD) (not requiring dialysis), anemia and type-2 diabetes (the Trial to Reduce Cardiovascular Endpoints with Aranesp((R)) Therapy, or TREAT), treatment (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - August 26, 2009 Category: Consumer Health News Tags: Diabetes Source Type: news

Amgen Announces Top-Line Results of Trial to Reduce Cardiovascular Events With Aranesp(R) TherapyEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Amgen (Nasdaq: AMGN) announced that in a large, randomized, double-blind, placebo-controlled, Phase 3 study of patients with chronic kidney disease (CKD) (not requiring dialysis), anemia and type-2 diabetes (the Trial to Reduce Cardiovascular Endpoints with Aranesp((R)) Therapy, or TREAT), treatment of anemia with Aranesp((R) )(darbepoetin alfa) to a hemoglobin target of 13 g/dL had no statistically significant effect on either of two primary endpoints compared with placebo treatment. (Source: World Pharma News)
Source: World Pharma News - August 25, 2009 Category: Pharmaceuticals Source Type: news

Amgen Announces Top-Line Results of Trial to Reduce Cardiovascular Events With Aranesp(R) Therapy (TREAT) in CKD Patients With Type-2 DiabetesEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
THOUSAND OAKS, Calif., Aug. 25 /PRNewswire-FirstCall/ -- Amgen (Nasdaq: AMGN) today announced that in a large, randomized, double-blind, placebo-controlled, Phase 3 study of patients with chronic kidney disease (CKD) (not requiring dialysis), anemia... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - August 25, 2009 Category: Pharmaceuticals Source Type: clinical trials

Amgen Announces Top-Line Results of Trial to Reduce Cardiovascular Events With Aranesp(R) Therapy (TREAT) in CKD Patients With Type 2 DiabetesEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
THOUSAND OAKS, Calif.—Aug. 25—Amgen (Nasdaq: AMGN) today announced that in a large, randomized, double-blind, placebo-controlled, Phase 3 study of patients with chronic kidney disease (CKD) (not requiring dialysis), anemia and type 2 diabetes (the Trial to Reduce Cardiovascular Endpoints with Aranesp((R)) Therapy, or TREAT), treatment of anemia with Aranesp(R) (darbepoetin alfa) to a hemoglobin target of 13 g/dL had no statistically significant effect on either of two primary endpoints compared with placebo treatment. (Source: Amgen News Service)
Source: Amgen News Service - August 24, 2009 Category: Pharmaceuticals Authors: pmannle at amgen.com Tags: Press Releases, Product News Source Type: organizations

Lipopolysaccharide evokes resistance to erythropoiesis induced by the long-acting erythropoietin analogue darbepoetin alfa in rats.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
CONCLUSION: LPS abolishes erythropoiesis and iron use evoked by DA and this is accompanied by a decrease in hemoglobin concentration and red blood cell concentration. Accordingly, endotoxin suppresses DAs ability to increase erythropoiesis. PMID: 19690235 [PubMed - in process] (Source: Anesthesia and Analgesia)
Source: Anesthesia and Analgesia - August 22, 2009 Category: Anesthesiology Authors: Brendt P, Horwat A, Schäfer ST, Dreyer SC, Göthert J, Peters J Tags: Anesth Analg Source Type: journals

Every-Other-Week Darbepoetin Alfa in the Correction and Maintenance of Haemoglobin Levels in Elderly Patients with Chronic Kidney Disease: Post Hoc Subanalysis of Data from Two Clinical TrialsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
(Source: Drugs)
Source: Drugs - August 19, 2009 Category: Geriatrics Authors: Krause, Michelle W.Raja, RasibAgarwal, AnilSilver, Marcia R.Scarlata, DebraSciarra, AngelaKewalramani, Reshma Tags: Original Research Articles Source Type: journals

Rationale and design of the oral HEMe iron polypeptide Against Treatment with Oral Controlled Release Iron Tablets trial for the correction of anaemia in peritoneal dialysis patients (HEMATOCRIT trial).Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
DiscussionThis investigator-initiated multicentre study has been designed to provide evidence to help nephrologists and their peritoneal dialysis patients determine whether HIP administration more effectively augments iron stores in ESP-treated PD patients than conventional oral iron supplementation.Trial Registration: Australia New Zealand Clinical Trials Registry number ACTRN12609000432213. (Source: BMC Nephrology)
Source: BMC Nephrology - July 27, 2009 Category: Urology & Nephrology Authors: Katherine BarracloughEuan NobleDiana LearyFiona BrownCarmel HawleyScott CampbellNicole IsbelDavid MudgeCarolyn van EpsJoanna SturtevantDavid Johnson Source Type: journals

Design of the Reduction of Events with Darbepoetin alfa in Heart Failure (RED-HF): a Phase III, anaemia correction, morbidity-mortality trialEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Background Patients with heart failure (HF) and anaemia have greater functional impairment, worse symptoms, increased rates of hospital admission, and a higher risk of death, compared with non-anaemic HF patients. Whether correcting anaemia can improve outcomes is unknown. Objective The Reduction of Events with Darbepoetin alfa in Heart Failure trial (RED-HF; Clinical Trials.gov NCT 003 58215) was designed to evaluate the effect of the long-acting erythropoietin-stimulating agent darbepoetin alfa on mortality and morbidity (and quality of life) in patients with HF and anaemia. Methods Approximately 2600 patients with New...
Source: European Journal of Heart Failure - July 23, 2009 Category: Cardiology Authors: McMurray, J. J.V., Anand, I. S., Diaz, R., Maggioni, A. P., O'Connor, C., Pfeffer, M. A., Polu, K. R., Solomon, S. D., Sun, Y., Swedberg, K., Tendera, M., van Veldhuisen, D. J., Wasserman, S. M., Young, J. B., on behalf of the RED-HF Committees and Invest Tags: CLINICAL TRIALS Source Type: journals

Epogen / Aranesp Class Action Again Dismissed By MDL As FDCA Private EnforcementEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
LOS ANGELES - The judge overseeing the Epogen/Aranesp off-label multidistrict litigation on June 17 again denied certification of a class of third-party payers, saying an amended complaint is still a private attempt to enforce violations of the Food, Drug and Cosmetic Act (FDCA) (In Re: Epogen/Aranesp Off-Label Marketing and Sales Practices Litigation, MDL Docket No. 1934, No. 08-ml-01934, C.D. Calif.; See 1/8/09, Page 14). Full story on lexis.com (Source: LexisNexis® Mealey's™ Emerging Drugs & Devices Legal News)
Source: LexisNexis® Mealey's™ Emerging Drugs & Devices Legal News - July 7, 2009 Category: Medical Law Source Type: info